The Growing GLP-1 Market Landscape: Key Insights for Pharma Marketers

People engaged in a discussion while reviewing a presentation on a laptop, sharing ideas and feedback.

From skyrocketing prescriptions to unprecedented ad spending, this report explores the GLP-1 landscape for pharma marketers planning for the next big wave in obesity and metabolic disorder treatments.

Inside this guide, you’ll find key insights on:

  • The evolving role of GLP-1 receptor agonists in patient care
  • Challenges such as drug shortages, insurance coverage, and safety concerns
  • FDA updates and risks related to compounded GLP-1 products
  • What’s next for GLP-1 medications: emerging treatments and innovations

Discover the noteworthy trends in this unique market space.

Download the report

View our Privacy Policy or Terms and Conditions.

Thank you

Your copy of our educational paper is ready to download.
Download now
Oops! Something went wrong while submitting the form.

1 O'Brien, J. (2024). MediaRadar CEO: What the ‘enormous’ increase in GLP-1 ad spend means. MM+M, https://www.mmm-online.com/home/channel/mediaradar-ceo-what-the-enormous-increase-in-glp-1-ad-spend-means/
2 Mahase, E. (2024). GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ, q1645. https://doi.org/10.1136/bmj.q1645
3 epocrates analytics